Former Roche site in Colorado, Corden Pharma, lays off 60 people

 
• By Eleanor Malone
  
Generate a summary of this article
Listen to this article
Beta

Less than two months after Roche sold its manufacturing facility in Boulder, Colorado, the new owners have announced plans to lay off 60 of its 260 workers. The renamed Corden Pharma Colorado, which was acquired by International Chemical Investors Group (ICIG) in September to incorporate into its Corden Pharma pharmaceutical platform, is to focus on contract manufacturing and development, according to local press reports.

Less than two months after Roche sold its manufacturing facility in Boulder, Colorado, the new owners have announced plans to lay off 60 of its 260 workers. The renamed Corden Pharma Colorado, which was acquired by International Chemical Investors Group (ICIG) in September to incorporate into its Corden Pharma pharmaceutical platform, is to focus on contract manufacturing and development, according to local press reports.

ICIG is a privately owned German/Luxembourg-registered industrial holding company which has acquired 17 independent chemicals and pharmaceutical businesses since its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.